-
Mashup Score: 10
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Elías Campo: "El coneixement generat durant vint anys de recerca al projecte del genoma de la leucèmia comença a arribar al pacient" - 7 month(s) ago
Director de l’IDIBAPS i catedràtic de la UB
Source: www.ara.catCategories: General Medicine News, Hem/OncsTweet-
https://t.co/uqe1KNBt81
-
-
Mashup Score: 35CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML - 8 month(s) ago
Key Points. CD70 targeted CAR-T cells secreting a CD33 T-cell engaging antibody molecule eradicate CD33 or CD70 deficient AML
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML https://t.co/6S2iUd0xwc
-
-
Mashup Score: 34
Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persis…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia | New England Journal of Medicine https://t.co/cIR8LJQ3UH
-
-
Mashup Score: 18
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692
-
-
Mashup Score: 18
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692
-
-
Mashup Score: 3
Chatbots are artificial intelligence (AI) programs designed to simulate conversations with humans that present opportunities and challenges in scientific research. Despite growing clarity from publishing organisations on the use of AI chatbots, researchers’ perceptions remain less understood. In thi …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scienti… https://t.co/ZKkOkkahiY
-
-
Mashup Score: 2Science in the Age of AI | AI for Science Forum - 8 month(s) ago
Eric Topol, Executive Vice President, Scripps Research, leads a conversation with:- Alison Noble, Oxford University Technikos Professor of Biomedical Enginee…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Science in the Age of AI | AI for Science Forum https://t.co/hgUJ6nFBIK via @YouTube
-
-
Mashup Score: 35CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML - 8 month(s) ago
Key Points. CD70 targeted CAR-T cells secreting a CD33 T-cell engaging antibody molecule eradicate CD33 or CD70 deficient AML
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML https://t.co/6S2iUd0xwc
-
-
Mashup Score: 14Abstract 4114505: Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma | Circulation - 8 month(s) ago
Introduction: Idecabtagene vicleucel (Ide-Cel) and ciltacabtagene autoleucel (Cilta-cel) are novel CAR-T therapies targeting B-cell maturation antigen (BCMA) and approved for relapsed and refractory multiple myeloma (RRMM). While cardiovascular adverse events (CVAE) are relatively common with CD-19 CAR-T, the incidence of CVAE in the real-world setting for anti-BCMA CAR-T in RRMM is largely unknown. This study aims to determine the incidence of CVAE and its associated risk factors in patients treated with ide-cel and cilta-cel. Method: This single-center retrospective cohort study evaluated RRMM patients treated with ide-cel and cilta-cel from May 2021 to December 2023. We assessed baseline cardiac and oncologic characteristics and clinical outcomes post-CAR-T. Cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome (ICANS) grading followed ASTCT consensus guidelines. Result: A total of 164 RRMM patients treated with ide-cel (N=109) or cilta-cel (N=55) with at le
Source: www.ahajournals.orgCategories: General Medicine News, Hem/OncsTweet-
Abstract 4114505: Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma | Circulation https://t.co/HyijqhuEoO
-
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | New England Journal of Medicine https://t.co/8LytRpPtLE